Mesoblast announced that its Phase 3 study of rexlemestrocel‑L for chronic low back pain has met its patient‑recruitment target of at least 300 patients, completing enrollment ahead of schedule. The milestone was announced on April 29 2026.
The trial, MSB‑DR004, is a placebo‑controlled, single intra‑discal injection study designed to confirm the pain‑reduction and opioid‑sparing benefits observed in the earlier MSB‑DR003 trial. The program is supported by the drug’s RMAT designation, which provides priority review and rolling review opportunities once a Biologics License Application is filed.
With recruitment complete, Mesoblast is moving closer to filing a BLA in Q3 2027 and expects top‑line data from the trial in mid‑2027. The company estimates that the therapy could address a market of more than 7 million U.S. patients and could generate peak annual revenues exceeding $10 billion if approved.
CEO Silviu Itescu said the milestone “is a major step toward delivering on our corporate goal of bringing to market a non‑opioid, disease‑modifying therapy for patients suffering from chronic low back pain, a condition with significant unmet medical need.” The achievement reduces execution risk for the pivotal trial and strengthens Mesoblast’s competitive position against other non‑opioid treatments in development.
The successful recruitment also supports Mesoblast’s broader strategy to expand its allogeneic MSC platform beyond pediatric graft‑versus‑host disease, building on the recent FDA approval of Ryoncil and the company’s ongoing financial performance driven by that product.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.